Results 91 to 100 of about 48,845 (222)
Efficacy of bevacizumab-doxycycline and sunitinib-hesperitin combinations on experimentally-induced corneal neovascularization [PDF]
Tıp Fakültesi, Göz Hastalıkları Ana Bilim DalıAmaç: Topikal aflibersept, sunitinib, bevacizumab-doksisiklin, sunitinib-doksisiklin ve sunitinib-hesperitin kombinasyonlarının korneal neovaskülarizasyon (KNV), apopitozis ve fibrozisi önleyici etkilerinin ...
Ekim, Yeliz
core +1 more source
Background Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as the first-line of treatment ...
Ninadh M. D’Costa +11 more
doaj +1 more source
Sunitinib Causes Macrocytosis in Patients with Advanced Renal Cell Carcinoma
Background: Sunitinib is approved for treatment of advanced renal cell carcinoma (RCC). Based on a clinical observation that patients receiving sunitinib developed macrocytosis, we undertook a study to further define this observation.
J. Price, R. Shaarbaf, L. Wood
core +1 more source
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü +3 more
wiley +1 more source
Patient‐derived xenograft (PDX) tumor models initiated in avian chorioallantoic membranes (CAM) are under investigation to evaluate the effectiveness of therapeutic options with the objective of personalizing treatments. CAM PDXs paired with ultra‐high frequency ultrasound (UHFUS) imaging could potentially constitute prospective high throughput assays ...
Sara Mar +5 more
wiley +1 more source
3158 Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model
OBJECTIVES/SPECIFIC AIMS: The aims of this study are threefold. Firstly, we are examining the effects of increased in vitro afterload (a proxy for hypertension) on human induced pluripotent stem cell cardiomyocyte (hiPSC-CM) response to sunitinib in a ...
Carissa Livingston +5 more
doaj +1 more source
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto +12 more
wiley +1 more source
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
Following approval of the oral, multitargeted tyrosine kinase inhibitor sunitinib malate for the treatment of patients with metastatic renal cell carcinoma (mRCC) in Europe and the USA in 2006, the agent has had a substantial impact on the treatment ...
Manuela Schmidinger +2 more
doaj +1 more source
Chemical structures of sorafenib and sunitinib.
Chemical structures of sorafenib and sunitinib.
Kazuhiko Yamashita (596927) +12 more
core +1 more source
Guillain-Barré Syndrome following Treatment with Sunitinib Malate [PDF]
Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects ...
Sandip Saha +4 more
core +1 more source

